Active Recombinant Human EPHA2 protein

• Cat.No.: EPHA2-2576H
• Product Overview: Active Recombinant Human EphA2/ECK Protein is produced by insect cell-baculovirus expression system. The target protein is expressed with sequence (Asp596-Ile976) of human EphA2 (Accession #NP_004422.2).

Specification

• Source: Baculovirus-Infected Sf9 Cells
• Species: Human
• Tag: Non
• Form: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized Human EphA2 at 1 μg/mL (100 μL/well) can bind Human EFNA1 with a linear range of 4.883 ng/mL-9.206 μg/mL.
• Molecular Mass: 43 kDa
• Protein Length: Asp596-Ile976
• Endotoxin: < 1.0 EU/μg of the protein by LAL method.
• Purity: > 95% by SDS-PAGE.
• Storage: Store the lyophilized protein at -20°C to -80 °C for long term.
  After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week.
• Reconstitution: Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water.

Gene Information

• Gene Name: EPHA2 EPH receptor A2 [ Homo sapiens ]
• Official Symbol: EPHA2
• Synonyms: EPHA2; EPH receptor A2; ECK, EphA2; ephrin type-A receptor 2; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK; epithelial cell receptor protein tyrosine kinase; ECK; CTPA; ARCC2; CTPP1
• Gene ID: 1969
• mRNA Refseq: NM_004431
• Protein Refseq: NP_004422
• MIM: 176946
• UniProt ID: P29317

Reviews

12/21/2022

The protein has low cytotoxicity.

02/03/2022

EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.

03/31/2021

Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.

Q&As

What are the treatment strategies for EPHA2?

Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.

How does EPHA2 expression level relate to the occurrence and progression of the disease?

The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.

How does EPHA2 expression level relate to tumor prognosis?

In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.

How can diseases be diagnosed by detecting EPHA2 expression levels?

Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.

Could EPHA2 be used as a target for the treatment of certain diseases?

Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.

What is the role of EPHA2 in cancer metastasis?

EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.